Currently, there are some candidate autoantibodies as clinically useful biomarkers for gastric cancer; namely, anti-p53, anti-carcinoembryonic antigen (CEA), anti-mucin, anti-survivin, and anti-livin autoantibodies. Here, BIRC5 is linked to gastric cancer.